The prognostic role of microRNA in epithelial ovarian cancer: a systematic review of literature with an overall survival meta-analysis

Abstract

Objective: To accomplish a systematic review of literature with overall survival meta-analysis about the role of microRNA in epithelial ovarian cancer as prognostic and predictive factor to chemotherapy response. Methods: A search was conducted in the PubMed database, using the keywords "microRNA" and "ovarian cancer" or "miRNA" and "ovarian cancer". Original articles published before 02/02/2019 that had as main subject microRNA (miRNA) and ovarian cancer were included. We considered for inclusion only studies that associated microRNA to chemotherapy-related diagnosis, prognosis, or response in ovarian cancer. Results: The literature search returned 1,482 articles, 497 of which fulfilled inclusion criteria, yielding 350 miRNAs. The status of each miRNA was assessed in serum and tissue of ovarian cancer, benign tumors, and healthy tissue. The status of up-/downregulation of miRNAs was related to prognostic features (overall survival and disease-free survival) and response predictive features such as platinum and paclitaxel sensitivity/resistance. The miRNAs that had been cited three or more times were selected for prognostic and response predictive features analysis. Twelve miRNAs fulfilled all these criteria and were included in the overall survival metaanalysis. Conclusions: miRNAs affect virtually all mechanisms of carcinogenesis, working as either oncogenes or tumor suppressor genes. In this systematic review we identified miRNAs that may be related to prognosis, diagnosis, and chemotherapy sensitivity. The 12 miRNAs identified here should be included in future studies for validation.

RETRACTED ARTICLE: Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression

“…These short miRNAs bind to the 3′-untranslated region (3′-UTRs) of their target genes through miRNA-response elements by complete or incomplete complementary base pairing, which results in translation suppression or target mRNA degradation [ 19 ]. miRNAs have also been demonstrated to be crucial regulators of EOC onset and progression and implicated in the control of multiple biological processes [ 20 , 21 ]. A close correlation between lncRNAs and miRNAs has been demonstrated during carcinogenesis and cancer progression.…”

Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs

“…Aberrant miRNA expression is associated with many diseases, including cancer, and miRNA-based drugs represent a novel and potentially powerful therapeutic approach [ 10 , 11 , 12 ]. Several studies have proposed using miRNAs as biomarkers for diagnosis, prediction and prognosis in cancer diseases, including AML [ 13 , 14 ]. Extracellular miRNAs, namely, those circulating in peripheral blood, seem to be attracting increasing attention from researchers.…”

Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression

“…Regarding EOC, a substantial amount of evidence has established that various lncRNAs are differentially expressed and function as tumor-inhibiting or tumor-promoting factors in regulating tumorigenesis [15][16][17]. microRNAs (miRNAs) are a class of single-stranded, non-coding RNA transcripts comprising [17][18][19][20][21][22][23][24] nucleotides [18]. These short miRNAs bind to the 3′-untranslated region (3′-UTRs) of their target genes through miRNA-response elements by complete or incomplete complementary base pairing, which results in translation suppression or target mRNA degradation [19].…”